4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2025)
Historic Income from Continuing Operations for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$56.9 million.
- 4D Molecular Therapeutics' Income from Continuing Operations fell 2968.16% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 4583.13%. This contributed to the annual value of -$160.8 million for FY2024, which is 5974.31% down from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Income from Continuing Operations stood at -$56.9 million, which was down 2968.16% from -$54.6 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Income from Continuing Operations registered a high of -$7.6 million during Q2 2021, and its lowest value of -$56.9 million during Q3 2025.
- For the 5-year period, 4D Molecular Therapeutics' Income from Continuing Operations averaged around -$31.6 million, with its median value being -$28.7 million (2023).
- As far as peak fluctuations go, 4D Molecular Therapeutics' Income from Continuing Operations skyrocketed by 6070.82% in 2023, and later tumbled by 33416.52% in 2024.
- 4D Molecular Therapeutics' Income from Continuing Operations (Quarter) stood at -$25.1 million in 2021, then decreased by 9.2% to -$27.4 million in 2022, then fell by 17.86% to -$32.3 million in 2023, then crashed by 53.85% to -$49.6 million in 2024, then dropped by 14.51% to -$56.9 million in 2025.
- Its last three reported values are -$56.9 million in Q3 2025, -$54.6 million for Q2 2025, and -$48.0 million during Q1 2025.